Study: FIT, colonoscopy more cost effective than Cologuard

A study comparing two colorectal cancer screening approaches found that a yearly fecal immunochemical test and a colonoscopy every 10 years was "more effective and less costly" compared with stool DNA test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) every three years. Results from the study, which was funded by Exact Sciences and led by researchers from Stanford University, were published Friday in Gastroenterology.

For Cologuard to be cost effective, a patient support program "would need to achieve substantially higher participation rates than those of FIT," or the test would need to cost 60% less than the base case used in the study, the authors wrote. ...